Total manufacturing prices throughout manufacturing platforms
The PCL platform displays the best manufacturing prices, adopted by the transient transfection platform, whereas the baculovirus an infection platform represents probably the most cost-effective choice (Fig. 2). When normalized by vg titer, nonetheless, the rating modifications: on the 2000 L scale, the price per 1 × 1012 vg for rAAV manufacturing is $260.8 for the PCL platform, $38.6 for the baculovirus an infection platform, and $30.8 for the transient transfection platform (Fig. 2D). This shift displays the affect of course of productiveness—notably vg titer—on unit price and underscores why cross-platform comparisons rely closely on productiveness assumptions. For instance, a latest case research reported ~10-fold larger upstream titers and >10-fold price reductions when shifting from HEK293 transfection to an Sf9-baculovirus platform [15, 17]. Individually, the present PCL platform sometimes delivers ~2 orders of magnitude decrease vg titers than transient transfection or baculovirus an infection platforms, translating into the next price per vg in step with the pattern noticed in our research [18]. Though transient transfection provides flexibility, it stays much less economical in comparison with the baculovirus an infection platform for large-scale manufacturing due to excessive USP materials prices, notably plasmids and transfection reagent. The baculovirus an infection platform delivers important price benefits at large-scale manufacturing however incurs further prices for baculovirus technology and banking (roughly 2.6% of whole manufacturing price per batch). PCL platform, regardless of its excessive preliminary improvement prices and royalty funds (roughly 0.9% of whole batch price), provides long-term price benefits if enough enhancements in productiveness could be achieved. As well as, though present implementations typically depend on perfusion, different working modes (e.g., fed-batch or hybrid methods) may additional enhance price effectivity by decreasing media consumption, probably leading to price constructions extra corresponding to baculovirus-based platforms. Nonetheless, such eventualities stay to be experimentally validated and must be interpreted as forward-looking concerns.
On a complete manufacturing price foundation, the PCL platform incurred the best price, adopted by transient transfection, whereas the baculovirus an infection platform was probably the most cost-eff ective. When normalized per 1×10¹² vg, the rating shifted, underscoring the influence of course of productiveness on unit price. A Uncooked materials price by course of stage (USP, DSP, DP, QC). B Conversion price by course of stage. C Materials price versus conversion price. D Manufacturing price per 1×10¹² vg. Panels A–C are proven for every platform with totals beneath every chart.
Determine 2 summarizes whole manufacturing prices throughout the foremost manufacturing platforms on the 2000 L scale. USP prices exceeded DSP prices for each the transient transfection and PCL platforms. Tradition media prices (a substantial contributor to uncooked materials price) are considerably larger in these platforms in comparison with the baculovirus an infection platform. The distinction arises primarily from (i) the necessity for supplemental vitamins resembling glutamine and glucose throughout manufacturing in transfection and PCL platforms – glutamine being important for mammalian cells however not required for insect cells within the baculovirus/Sf9 platform—and (ii) the widely decrease unit price of insect cell media relative to mammalian cell media, leading to decreased USP price burdens for the baculovirus/Sf9 platform. For the transfection platform, USP prices considerably exceeded these of DSP, DP, and QC operations, primarily as a result of further main bills related to plasmids, transfection reagent, and elective boosters required on this platform. Notably, within the baculovirus/Sf9 platform, DSP processing prices exceeded USP prices as a result of the baculovirus course of omits pricey transfection and perfusion-related uncooked supplies, thereby yielding decrease USP bills relative to the opposite platforms.
Conversion price breakdowns throughout USP, DSP, DP, and QC have been comparatively related for all three platforms. This similarity primarily displays the an identical working scale used throughout platforms, which yielded comparable allocations of conversion prices.
Whereas uncooked supplies and consumables meaningfully contribute to total manufacturing prices in biologics manufacturing at CMOs, conversion prices—facility, labor, and overhead—typically dominate at massive scale [19]. In our evaluation, this sample was noticed just for the baculovirus/Sf9 platform. For the transfection and PCL platforms, substantial direct-material expenditures related to transient transfection (e.g., plasmids, transfection reagent, elective enhancers) and perfusion operations (e.g., ATF {hardware} and consumables) shifted the stability, making direct supplies—not conversion prices—the first price drivers.
Comparative price evaluation of upstream supplies
Determine 3 illustrates the distribution of USP uncooked materials prices throughout the three main rAAV manufacturing platforms. Total, USP uncooked materials prices are 7.7-fold and 6.2-fold larger within the PCL and transfection platforms, respectively, in contrast with the baculovirus an infection platform on the 2000 L scale. Within the transient transfection platform, the foremost price parts embody plasmids, media, transfection reagent, and Benzonase, which collectively account for greater than 94% of the general USP materials price. Extra price contributors embody SU baggage and miscellaneous gadgets resembling filters and manifolds. In distinction, the baculovirus an infection platform has prices extra evenly distributed amongst numerous classes. Though the first price drivers are media, Benzonase, and BIICs, which collectively account for 76% of the general USP materials price, further bills resembling SU consumables and miscellaneous gadgets are comparatively evenly distributed. The PCL perfusion-based platform reveals a skewed USP price distribution dominated by media, reflecting the excessive consumption inherent to perfusion. Media alone accounts for 68% of the USP materials price, whereas SU baggage and alternating tangential circulate (ATF) filters collectively contribute roughly 21%. In distinction to the opposite two platforms, the PCL perfusion platform exhibited a comparatively decrease endonuclease (e.g., Benzonase) price ratio as a result of excessive media price. Conversely, the share of single-use bag prices was larger than within the different platforms, reflecting the consumable depth of perfusion. As a result of endonuclease is a notable price burden in rAAV manufacturing, perfusion could be an efficient lever for materials price discount—supplied it delivers enough productiveness to offset the added single-use and perfusion-related bills.
The transient transfection platform is primarily pushed by plasmids, media, and transfection reagent, whereas the baculovirus an infection platform reveals a extra balanced price distribution. The PCL perfusion-based platform is dominated by media prices due to the excessive media consumption related to perfusion operation.
Comparative price evaluation of downstream supplies
Determine 4 illustrates the distribution of downstream uncooked materials prices throughout the three manufacturing platforms on the 2000 L manufacturing scale. Total, every platform follows the same downstream sequence: clarification, harvest tangential circulate filtration (hTFF) (aside from the baculovirus an infection platform), affinity chromatography, AEX chromatography, viral reductive filtration (VRF), and remaining TFF. Buffer preparation represents 23–32% of whole downstream uncooked materials prices throughout all platforms. It’s the largest price driver in transient transfection platform and nonetheless a serious contributor within the different platforms. The price of water for injection (WFI) was negligible and thus excluded from all buffer preparation calculations. Clarification, hTFF, and affinity seize comply with as secondary price drivers, with their relative significance and related prices differing by platform.
The transient transfection platform incurs the best DSP materials price ($809 ok), adopted by the PCL platform ($724 ok) and the baculovirus an infection platform ($506 ok). Buffer preparation is a serious price contributor throughout all platforms, whereas clarification and affinity chromatography are key price drivers within the PCL and baculovirus an infection platforms, respectively.
Clarification prices are largely pushed by the dimensions and complexity of the feed stream, with filter space and depth filter utilization growing sharply for high-cell-density or lysed harvests. For hTFF, prices stem primarily from using massive membrane floor areas and single-use cassettes, which scale straight with course of quantity.
The share contribution of affinity chromatography varies considerably between platforms. Within the baculovirus an infection platform evaluated right here, which lacks an hTFF step, the affinity column was outsized to allow direct seize of upstream materials with out prior quantity discount. This configuration required bigger resin volumes to keep away from excessively lengthy loading instances, thereby growing materials price. As well as, impurities resembling host-cell DNA and protein, that are partially eliminated throughout hTFF in different platforms, stay current within the baculovirus harvest. These impurities sometimes enhance viscosity and might foul the resin, successfully decreasing obtainable binding capability and seize effectivity. Related observations have been reported for protein A chromatography in mAb manufacturing [20, 21]. Collectively, these process-specific elements clarify why affinity prices for the baculovirus an infection platform are markedly larger than within the different platforms.
AEX chromatography is comparatively cheap throughout platforms, contributing solely 6–12% of whole downstream materials prices. Lastly, VRF and remaining TFF every account for a small fraction of downstream uncooked materials prices (lower than 5%).
Manufacturing price discount methods
Scale-up and price effectivity
Scale-up considerably reduces whole manufacturing price for rAAV-based therapeutics. When the transient transfection course of is scaled from 50 L to 2000 L—a 40-fold enhance in manufacturing quantity at a continuing USP titer of 5.0 × 10¹¹ vg/mL and an total DSP restoration of 23% as reported within the Supplementary Info (Desk S3)—the overall price will increase from $1.24 M to $4.53 M, representing solely a 3.56-fold enhance (Fig. 5A). Moreover, the ratio of conversion to materials price decreases sharply with scale, from about 3.35 at 50 L to 0.68 at 2000 L. This displays that conversion prices—pushed by labor, facility overhead, and different fastened operational bills—don’t scale linearly with manufacturing quantity and grow to be diluted at bigger scales. In distinction, materials prices resembling plasmids, transfection reagent, and chromatography resins scale proportionally with batch measurement, resulting in a decrease conversion-to-material price ratio at larger manufacturing scales.
Prices have been modeled for a transient transfection rAAV course of at 4 scales (50, 250, 500, 2000 L), revealing that bigger scales markedly enhance price effi ciency. A Whole manufacturing price per batch as stacked bars cut up into materials (darkish blue) and conversion (orange) price, with section labels exhibiting every share. As scale will increase, fastened conversion prices are diluted and the fabric share rises shifting the price construction towards consumables. B Value per dose, which fell 10.4-fold from 50 L to 2000 L, the dominant driver of improved dose economics. C Materials price per batch cut up throughout upstream (USP, darkish blue), downstream (DSP, orange), high quality management (QC, inexperienced), and drug product (DP, purple); USP stays the biggest material-cost element at each scale, marking upstream consumables as the important thing goal for additional price discount.
As proven in Fig. 5B, scaling up manufacturing results in a considerable discount in price per dose. For the transient transfection platform described earlier and assuming Duchenne muscular dystrophy because the medical indication (2.8 × 10¹⁵ vg/dose), the price per dose decreases from $892k at 50 L to $86k at 2000 L, representing an total price discount of 10.4-fold. Equally, the price per 1 × 10¹² vg at BDS (Bulk Drug Substance) decreases sharply from $320 at 50 L to $31 at 2000 L, demonstrating pronounced economies of scale throughout the transient transfection platform.
Fig. 5C reveals the variation in materials price throughout completely different manufacturing scales for rAAV manufacturing utilizing the transient transfection course of. The full materials price per batch will increase markedly with scale, rising from roughly $0.29 M at 50 L to $2.7 M at 2000 L. The price construction additionally evolves as the method scales up. On the 50 L scale, USP, DSP, QC, and DP contribute roughly 28%, 26%, 42%, and 4% of the overall price, respectively. With growing scale, USP materials price turns into progressively dominant—accounting for about 45% at 250 L, 56% at 500 L, and 66% at 2000 L. In distinction, the proportional contributions of DSP, QC, and DP lower to 29%, 4%, and 1%, respectively, at 2000 L. These outcomes point out that whereas whole materials prices rise with scale, the rise is basically pushed by USP uncooked supplies and consumables, reflecting their sensitivity to reactor quantity and manufacturing scale. DSP and QC parts develop extra modestly, highlighting improved material-use effectivity at bigger scales.
One other benefit of scale-up is {that a} smaller fraction of the overall vial depend is consumed by QC launch testing. As a result of 20–40 vials are sometimes allotted for launch, this fastened requirement represents a a lot smaller proportion of larger-scale batches, thereby growing the quantity of fabric obtainable for affected person dosing [22, 23].
Course of improvement and optimization
USP and DSP course of improvement and optimization—whether or not aimed toward growing USP productiveness, decreasing uncooked materials consumption, or intensifying unit operations—can considerably decrease the general price per dose. Right here we determine key areas of course of optimization that drive price effectivity and quantitatively assess the ensuing financial savings when scaled to 2000 L manufacturing. For USP improvement, two optimization eventualities have been evaluated. The primary concerned a two-step optimization of the transient transfection course of utilizing a High quality-by-Design Design-of-Experiment (DOE) strategy. The second targeted on course of intensification by implementation of a perfusion-based USP technique. In DSP, we quantified price financial savings related to resin reuse and additional demonstrated that optimization of the AEX chromatography step can enhance the proportion of full capsids with out considerably affecting step yield, therefore the batch price.
Transfection course of optimization
Within the first case research, the transient transfection course of was optimized by adjusting the overall DNA quantity, plasmid ratios, and viable cell density on the time of transfection. The vg titers at harvest for the benchmark, DOE1-optimized, and DOE1 + DOE2-optimized processes have been 6.0 × 10¹⁰ vg/mL, 2.9 × 10¹¹ vg/mL, and eight.8 × 10¹¹ vg/mL, respectively. Particulars of the optimization could be discovered within the Supplementary Info (Part 4: Transfection Course of Optimization). Assuming scale-up of this course of to a 2000 L bioreactor for a neurodegenerative illness requiring 9.1 × 1013 vg/kg of affected person weight (2.8 × 10¹⁵ vg/dose), the benchmark, DOE1-optimized, and DOE1 + DOE2-optimized processes would yield enough materials to deal with 8, 38, and 116 sufferers, respectively—representing greater than a 14-fold enhance in affected person protection.
This substantial acquire in productiveness was accompanied by a rise in whole materials price for the DOE-optimized processes. As proven in Fig. 6, the DOE1- and DOE1 + DOE2-optimized processes incurred 47% and 69% larger materials prices, respectively, when scaled to 2000 L manufacturing. This enhance was as a result of larger DSP purification prices ensuing from improved USP titers in each DOE1 and DOE2 optimizations. Moreover, USP materials prices rose by roughly 50% within the DOE1-optimized course of as a result of elevated DNA and transfection reagent utilization. Since DOE2 optimization targeted solely on plasmid ratio adjustment, its whole USP price remained largely unchanged at roughly $2.1 M. Regardless of these will increase in materials price, the general price per dose was decreased by ~74% (from $458k to $117k) and ~91% (from $458k to $42k) for the DOE1- and DOE1 + DOE2-optimized processes, respectively.
Optimization of the triple-plasmid transfection course of considerably elevated vg titers, leading to an roughly 14-fold enhance in affected person protection. Regardless of larger materials prices for the DOE-optimized processes, the general price per dose was considerably decreased, demonstrating improved course of effectivity and scalability.
Adjustments in vg titer could be accompanied by shifts within the full-to-empty capsid ratio, which can influence downstream purification effectivity and total restoration. Due to this fact, it’s vital to optimize % full capsid throughout USP to keep away from inserting further burden on downstream purification steps by the necessity to take away empty and partial capsids, which may negatively have an effect on yield.
USP intensification through perfusion
Whereas the vast majority of rAAV USP manufacturing processes depend on fed-batch operation, course of intensification by perfusion can additional improve productiveness, scale back course of footprint, and supply important financial benefits. On this case research, a benchmark fed-batch course of was transformed to a perfusion-based rAAV manufacturing course of. Two configurations have been evaluated: the primary using perfusion solely previous to transfection, and the second incorporating perfusion each earlier than and after transfection. The vg titers at harvest for the perfusion-pre-transfection and perfusion-pre-and-post-transfection processes have been 3.4 × 10¹¹ vg/mL, and 9.4 × 10¹¹ vg/mL, respectively. Particulars of the perfusion methods are supplied within the Supplementary Info (Part 5: USP Intensification through Perfusion). Assuming scale-up to a 2000 L bioreactor for a neurodegenerative illness requiring 9.1 × 1013 vg/kg of affected person weight (2.8 × 10¹⁵ vg/dose), the benchmark, perfusion-pre-transfection, and perfusion-pre-and-post-transfection processes would yield enough materials to deal with 8, 45, and 123 sufferers, respectively—representing a greater than 15-fold enhance in affected person protection.
The elevated productiveness achieved by perfusion was accompanied by larger whole uncooked materials prices. As proven in Fig. 7, the perfusion-pre-transfection and perfusion-pre-and-post-transfection processes incurred 333% and 456% larger materials prices, respectively, when scaled to 2000 L manufacturing. This enhance was primarily pushed by the extra media, plasmids, and transfection reagent required for perfusion-based operation, in addition to elevated DSP purification prices related to improved USP titers. Regardless of these will increase in materials price, the general price per dose—assuming manufacturing on the 2000 L scale for the neurodegenerative illness mannequin described earlier—was decreased by roughly 62% (from $458k to $176k) and 82% (from $458k to $82k) for the perfusion-pre-transfection and perfusion-pre-and-post-transfection processes, respectively.
Changing a fed-batch course of to perfusion-based rAAV manufacturing considerably elevated vg titers, leading to a greater than 15-fold enhance in affected person protection. Regardless of larger materials prices for the perfusion processes, the general price per dose was dramatically decreased, demonstrating the financial advantages of course of intensification.
